
Engage with experts Klaus Rabe, Stephanie Christenson, and Paola Rogliani in an educational symposium to explore the inflammatory pathways and phenotypes of COPD, investigate the genetic associations of IL-33 and COPD, examine early preclinical findings, and review ongoing research on the role of IL-33 in COPD.
Dr. Nicola Hanania explains the vicious cycle of exacerbations and lung function decline observed in COPD.

Join global expert Dr. Eric Bateman as he discusses how exacerbations in patients with COPD are different than exacerbations in patients with asthma.

Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.

Dr. Stella Lee explores the past, present and future implementation of guidelines into daily practice
Professor Joost Meijer discusses the complex etiology and diagnosis of BP

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

In this video from EADV 2025, Dr. Donna Culton discusses the clinical features, diagnosis, and burden of BP
Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.